Related Experiment Videos

Metabolism of lofepramine by rat liver microsomes

Insights

Lofepramine metabolism in rats involves cytochrome P-450 enzymes, producing desmethylimipramine. Enzyme activity increased after phenobarbital or 3-methylcholanthrene pretreatment, with lofepramine inhibiting aniline hydroxylation.

Area of Science:

  • Pharmacology
  • Biochemistry
  • Drug Metabolism

Background:

  • Lofepramine is an antidepressant drug.
  • Understanding its metabolic pathways is crucial for drug development and safety.
  • Cytochrome P-450 enzymes play a significant role in drug metabolism.

Purpose of the Study:

  • To investigate the in vitro metabolism of lofepramine using rat liver microsomes.
  • To identify the key metabolites of lofepramine.
  • To explore the involvement of cytochrome P-450 enzymes and the effects of enzyme induction on lofepramine metabolism.

Main Methods:

  • In vitro incubation of lofepramine with rat liver microsomes.
  • Analysis of metabolites using appropriate biochemical techniques.
  • Enzyme kinetic studies (Vmax, Km) to assess metabolic activity.
  • Investigation of enzyme induction using phenobarbital and 3-methylcholanthrene.

Main Results:

  • Lofepramine is metabolized by a cytochrome P-450-dependent enzyme system.
  • Major metabolites identified include desmethylimipramine (DMI), formaldehyde, and p-chlorobenzoic acid.
  • Phenobarbital and 3-methylcholanthrene pretreatment enhanced lofepramine metabolism by increasing Vmax, without altering Km.
  • Lofepramine, imipramine, and DMI competitively inhibited aniline hydroxylation, with lofepramine being the most potent inhibitor.

Conclusions:

  • Lofepramine metabolism is mediated by cytochrome P-450 enzymes.
  • Enzyme induction significantly enhances lofepramine metabolic activity.
  • Lofepramine exhibits inhibitory effects on the metabolism of other drugs, such as aniline, suggesting potential drug-drug interactions.

Related Concept Videos